However, so far, only vascular endothelial growth factor receptor (VEGFR) antibody ramucirumab1 and VEGFR‐targeted tyrosine kinase inhibitor (TKI) apatinib2 have showed slight advantage of survival in the second‐ and third‐line therapy of advanced GC, respectively. Here, KDR is linked to gastric cancer.